Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abeona Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed commercial-stage biopharmaceutical company with common stock traded as ABEO. Recent Form 8-K reports cover operating results, ZEVASKYN commercial launch disclosures, completion of the sale of a Rare Pediatric Disease Priority Review Voucher received after FDA approval of ZEVASKYN, and other material events.
Proxy and governance filings describe annual meeting procedures, board composition, committee assignments, director independence, compensation matters, and amendments to the company’s bylaws. Those bylaws disclosures address stockholder meeting mechanics, virtual meetings, proposal and nomination procedures, quorum requirements, and other Delaware corporate governance provisions.
ABEONA THERAPEUTICS INC. (ABEO) director Mark Alvino reported selling 15,000 shares of common stock on 2026-09-01 in an open-market or private transaction. The weighted average sale price was $5.8644 per share, with individual trades executed between $5.80 and $5.9250 per share. Following this sale, Alvino directly holds 62,065 shares of ABEO common stock.
ABEONA THERAPEUTICS INC. (ABEO) director Mark Alvino has filed a notice to sell common stock under Rule 144. The planned sale covers 15,000 shares of common stock through broker Stifel Nicolaus & Company Inc., with an aggregate market value of $87,966.00, and is listed for 09/01/2026 on Nasdaq. The shares relate to Restricted Stock Awards granted as equity compensation on 08/26/2025 (1,614 shares) and 01/31/2026 (13,386 shares).
Montanova Capital, LLC and Aaron Cowen report their beneficial ownership of Abeona Therapeutics Inc. common stock on an amended Schedule 13G. They each report beneficial ownership of 500,000 shares of common stock, representing 0.9% of the outstanding class.
Both reporting persons have shared voting and dispositive power over 500,000 shares and no sole voting or dispositive power. They indicate that they now hold 5 percent or less of the class. Each reporting person disclaims beneficial ownership of the securities beyond any pecuniary interest.
Abeona Therapeutics Inc. reported its first full quarters of product revenue from ZEVASKYN for the period ended June 30, 2026. Product revenue, net, reached $11.4 million for the quarter and $20.1 million for the first six months of 2026, compared with none in the prior-year periods. Total revenues were the same amounts, as there were no 2026 license revenues.
The company recorded a quarterly net loss of $20.2 million and a six‑month net loss of $37.3 million, versus net income of $108.8 million and $96.8 million in the comparable 2025 periods, which had included a $152.4 million gain from the sale of a priority review voucher. Loss from operations narrowed year over year.
Cash and cash equivalents were $56.2 million and short‑term investments were $90.6 million as of June 30, 2026, with net cash used in operating activities of $37.3 million for the first half. Total debt under the term loan was $15.0 million and warrant liabilities were carried at fair value of $20.7 million. Management states that existing capital resources are expected to fund operations for at least 12 months from issuance of these statements.
Abeona Therapeutics Inc. reported second quarter 2026 results centered on the commercial launch of ZEVASKYN, its autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). Net ZEVASKYN revenue for the quarter ended June 30, 2026 was $11.4 million, a 31% quarter-over-quarter increase from $8.7 million in the first quarter of 2026. Five patients were treated in the quarter, with revenue recognized for four treatments; since launch, 12 treatments have been completed.
The qualified treatment center (QTC) network expanded to seven sites, including recent activations at NewYork-Presbyterian/Columbia, Children’s Hospital of Philadelphia, University of Texas Medical Branch, and Cincinnati Children’s. Abeona highlighted that the Centers for Medicare & Medicaid Services granted ZEVASKYN New Technology Add-On Payment (NTAP) status effective October 1, 2026, intended to support hospital adoption for Medicare patients, who account for about 10% of RDEB patients.
R&D expenses were $5.0 million and SG&A expenses were $15.8 million in Q2 2026, both down versus Q1 2026. The company reported a net loss of $(20.2) million, or $(0.35) per share, and held $146.8 million in cash, cash equivalents and short-term investments as of June 30, 2026, compared with $191.4 million as of December 31, 2025.
Vazzano Joseph Walter reported reported sale transactions in this Form 4 filing.
Abeona Therapeutics Chief Financial Officer Joseph Walter Vazzano reported that 1,478 shares of common stock were withheld at $6.53 per share to satisfy tax withholding obligations upon vesting of restricted stock awards. After this tax-related withholding, he directly holds 492,079 shares.
Abeona Therapeutics Inc. filed a prospectus supplement updating a previously effective resale registration for up to 15,219,758 shares of common stock. The update reflects the assignment of 760,870 Common Warrants from Point72 Associates, LLC to SILV Fund, Ltd., without changing the aggregate number of registered shares.
The company will not receive proceeds from any resale of shares by the selling stockholders, but will receive cash proceeds from any warrant exercises. Abeona's common stock trades on The Nasdaq Capital Market under the symbol ABEO, and the closing price on July 7, 2026 was $6.55 per share. Investors are directed to the incorporated risk factors and reports for a detailed discussion of risks.
Abeona Therapeutics Inc. Chief Financial Officer Joseph Walter Vazzano reported an open-market sale of 24,880 shares of common stock at a weighted average price of $6.9637 per share. According to the filing, this sale was made to cover tax obligations tied to the vesting of restricted stock awards.
After this transaction, he directly holds 493,557 shares of Abeona common stock. The price reflects multiple trades executed between $6.86 and $7.04 per share.
Abeona Therapeutics Inc. chief executive officer Vishwas Seshadri reported an open-market sale of 67,971 shares of common stock at a weighted average price of $6.9637 per share. According to the filing, the sale was made to cover tax obligations from vesting restricted stock awards, and he continued to hold 1,306,108 shares afterward.
Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O'Malley sold 12,050 shares of common stock on July 9, 2026 at a weighted average price of $6.9637 per share.
The company notes this sale was made to cover tax obligations from vesting of restricted stock awards. After the sale, O'Malley directly holds 427,953 shares of Abeona Therapeutics common stock.